Share
.webp)
.webp)
.webp)
.webp)
Kyle Kuvalanka
Aktis Oncology, Inc., a clinical-stage biotechnology company developing targeted radiopharmaceutical therapies for underserved cancer patient populations, has appointed Kyle Kuvalanka as Chief Financial Officer (CFO).
This strategic leadership addition comes at a pivotal time as the company accelerates its clinical programs and expands its corporate development initiatives.
Mr. Kuvalanka brings more than two decades of senior leadership experience in the biopharmaceutical industry, coupled with deep expertise in capital markets, strategic finance, and operational growth. Since 2013, he has served in multiple C-suite roles across both public and private biotechnology companies. Most recently, he was CFO and Chief Business Officer at ROME Therapeutics, and previously served as CFO and Chief Operating Officer at Goldfinch Bio. In these roles, he played an instrumental part in establishing financial strategy, driving business development, and supporting organizational scale-up.
Before these positions, Mr. Kuvalanka served as Chief Operating Officer at Syros Pharmaceuticals and Chief Business Officer at Blueprint Medicines, where he led finance and business operations and helped guide both companies through successful initial public offerings. Earlier in his career at Millennium Pharmaceuticals (now the Takeda Oncology Company), he held leadership roles in business development, corporate strategy, alliance management, and investor relations, contributing significantly to the company’s strategic growth.
Kyle Kuvalanka holds an MBA from the Wharton School of the University of Pennsylvania and a BA from Wesleyan University. His appointment marks a significant step in strengthening Aktis Oncology’s financial and strategic capabilities as it continues its advancement in the radiopharmaceutical oncology landscape.
